Ionis flashes new Angelman syndrome data, will pursue Phase 3 trial next year

Max Gelman

Senior Editor

Ionis on Monday revealed new six-month data from its Angelman syndrome program, presenting Phase 1/2a results from a pooled group of patients taking three different …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ionis flashes new Angelman syndrome data, will pursue Phase 3 trial next year

Max Gelman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Io­n­is flash­es new An­gel­man syn­drome da­ta, will pur­sue Phase 3 tri­al next year

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Ionis flashes new Angelman syndrome data, will pursue Phase 3 trial next year